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The function of the cystic fibrosis transmembrane
conductance regulator (CFTR) as a Cl2 channel in the
apical membrane of epithelial cells is extensively docu-
mented. However, less is known about the molecular
determinants of CFTR residence in the apical mem-
brane, basal regulation of its Cl2 channel activity, and
its reported effects on the function of other transport-
ers. These aspects of CFTR function likely require spe-
cific interactions between CFTR and unknown proteins
in the apical compartment of epithelial cells. Here we
report that CFTR interacts with the recently discovered
protein, EBP50 (ERM-binding phosphoprotein 50).
EBP50 is concentrated at the apical membrane in hu-
man airway epithelial cells, in vivo, and CFTR and
EBP50 associate in in vitro binding assays. The CFTR-
EBP50 interaction requires the COOH-terminal DTRL
sequence of CFTR and utilizes either PDZ1 or PDZ2 of
EBP50, although binding to PDZ1 is of greater affinity.
Through formation of a complex, the interaction be-
tween CFTR and EBP50 may influence the stability
and/or regulation of CFTR Cl2 channel function in the
cell membrane and provides a potential mechanism
through which CFTR can affect the activity of other
apical membrane proteins.
Cystic fibrosis (CF)1 is a lethal autosomal recessive disease
characterized by defects in epithelial ion transport (1). CF is
caused by mutation in the gene coding for the cystic fibrosis
transmembrane conductance regulator (CFTR), which func-
tions as a cAMP-regulated Cl2 channel at the apical cell sur-
face (1–3). The CF phenotype includes changes in cellular pro-
cesses distinct from those involving Cl2 transport, including
sodium hyperabsorption and abnormalities in the processing of
mucins (4–6). The most common cause of CF are mutations
that lead to the formation of an abnormally folded CFTR pro-
tein that does not reach the cell surface (2). Even wild type
CFTR is inefficiently transported to the cell surface, with up to
70% of the newly synthesized proteins failing to achieve a
stable conformation that escapes quality control mechanisms
in the endoplasmic reticulum (2, 7, 8). Knowledge of the pro-
tein-protein interactions that are involved in CFTR-mediated
regulation of other epithelial transport proteins, and the inter-
actions that control the trafficking, localization, and regulation
of CFTR, is incomplete. Recently, the amino terminus of CFTR
was shown to interact with syntaxin 1, with implications both
for insertion of CFTR into the plasma membrane and regula-
tion of channel activity (9). Other interactions that stabilize
CFTR or regulate its function remain to be identified.
Compartmentalization of CFTR in a multiprotein complex
might regulate CFTR activity by stabilizing the protein at the
cell surface or by increasing the efficiency by which kinases and
phosphatases control the channel. The presence of such a com-
plex may also explain how CFTR modulates the activity of
other epithelial cell transport proteins. A common mechanism
to establish multiprotein complexes is via protein-protein in-
teractions with submembranous scaffolding proteins (10–12).
Ion channels and transport proteins may associate via their
COOH-terminal cytosolic tails with proteins that contain PDZ
domains (13–16). PDZ domains (originally identified in
postsynaptic density-95, discs large, and ZO-1) are found in a
large number of multifunctional proteins, where they mediate
protein-protein interactions at structures including the
postsynaptic density in neurons and junctional complexes in
epithelia (10–12, 17). There is a short consensus sequence at
the COOH terminus of membrane proteins that is critical for
the interaction with PDZ domains; one consensus sequence
consists of the amino acids (D/E)(T/S)XV (10, 18).
The COOH-terminal cytosolic domain of CFTR is highly con-
served across species and terminates with the amino acids
DTRL (1). Therefore, we reasoned that CFTR may exist in a
multiprotein complex at the apical plasma membrane via in-
teraction with a PDZ-containing scaffolding protein. Although
several PDZ-containing proteins are known to be expressed in
epithelia, many, including ZO-1 and ZO-2, are largely re-
stricted to junctional complexes (19, 20). Recently, a 50-kDa
human protein containing two PDZ domains was identified and
cloned based on its ability to associate with ezrin, a protein
found in the apical domain of epithelial cells (21). This protein,
ERM-binding phosphoprotein 50 (EBP50), is also localized at
the apical surface and is expressed in a variety of epithelial
tissues (21). Human EBP50, and its rabbit homologue NHE-RF
(Na1/H1 exchange regulatory factor) share domain organiza-
tion and sequence homology with E3KARP (NHE3 kinase A
regulatory protein), and both proteins may associate with the
Na1-H1 exchanger NHE3 to confer cAMP-mediated inhibition
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of Na1-H1 exchange (22, 23). In addition, the COOH terminus
of the b2-adrenergic receptor has recently been shown to asso-
ciate with the first PDZ domain of EBP50 (24). We determined
the distribution of EBP50 in human airway epithelia and stud-
ied the biochemical interaction between EBP50 and CFTR. The
identification of proteins that associate with CFTR, either di-
rectly or via scaffolding proteins, will facilitate our understand-
ing of why absence of CFTR leads to severe abnormalities in
epithelial cell function.
MATERIALS AND METHODS
Analysis of EBP50 Expression and Distribution—Polyclonal anti-
serum B60 directed against the COOH terminus of EBP50 was gener-
ated in rabbits as described (21). Sections from human bronchus were
fixed in 4% paraformaldehyde and permeabilized as described (25). The
sections were subsequently blocked in 20% normal goat serum in 50 mM
sodium phosphate, pH 7.4, 150 mM NaCl (PBS) and incubated in anti-
serum B60 or pooled normal rabbit sera diluted 1:50 in PBS. Texas
Red-conjugated goat anti-rabbit IgG (Jackson ImmunoResearch, West
Grove, PA) was used as secondary antibody. Tissues were mounted in
Vectashield containing 4,6-diamidino-2-phenylindole to label nuclei
(Vector Laboratories, Burlingame, CA).
For immunoblot analysis, cultured cells were homogenized in 20 mM
NaCl, 5 mM EDTA, 1 mM EGTA, 20 mM Hepes, pH 7.2 (Buffer A), 1%
Triton X-100 1 protease inhibitors (26), centrifuged 14,000 3 g for 20
min, and the supernatant collected. To analyze the distribution of
proteins in soluble and particulate fractions, cells were homogenized in
the same buffer minus Triton X-100, homogenates were centrifuged at
413,000 3 g for 20 min, and pellets were resuspended in Buffer A 1
0.2% SDS. Protein concentrations of whole cell lysates or soluble and
particulate fractions were determined using the BCA assay kit (Pierce).
Samples (20 mg) were electrophoresed on SDS-PAGE gels and analyzed
by Western blot analysis as described previously (26). Mouse anti-ezrin
was obtained from Transduction Laboratories (Lexington, KY), and
rabbit anti-CFTR R domain antiserum was described previously (27).
Plasmids for Bacterial Expression and Purification of Fusion Pro-
teins—Full-length EBP50 (amino acids 1–358), PDZ1 (amino acids
1–97), and PDZ2 (amino acids 139–248) of EBP50 were expressed as
GST fusion proteins from constructs created either by PCR amplifica-
tion or subcloning of sequences from human EBP50 cDNA. PCR prod-
ucts were generated with unique restriction sites on their ends, and the
fragments to be subcloned were directionally ligated into the polylinker
of the appropriate pGEX vector (Amersham Pharmacia Biotech). All
PCR products were verified by DNA sequencing and found to be free of
mutations.
Full-length GST-EBP50 or fusion proteins containing domains of
EBP50 were expressed in Escherichia coli DH5a by induction with 1
mM isopropyl-b-D-thiogalactopyranoside for 3 h at 37 °C. Bacterial ly-
sates were prepared by sonication in ice-cold PBS in the presence of
protease inhibitors; proteins were purified from the soluble fraction on
glutathione-Sepharose 4B.
Gel Overlays—Five-hundred ng of GST-EBP50, GST-PDZ1, GST-
PDZ2, or GST-b2-syntrophin PDZ domain were electrophoresed on 10%
SDS-PAGE gels and transferred to nitrocellulose membranes. Blots
were blocked in 10% non-fat dry milk in 150 mM NaCl, 50 mM Tris-HCl,
pH 7.4 1 0.05% Tween 20 (TTBS) and probed with 100 nM biotinylated
CFTR peptide diluted in TTBS for 2 h at room temperature. After
extensive washing in TTBS, the membranes were incubated with
streptavidin-conjugated horseradish peroxidase diluted 1:10,000 in
TTBS. Blots were developed using enhanced chemiluminescence (ECL).
Peptide or Fusion Protein Affinity Chromatography—Peptides corre-
sponding to the COOH-terminal 22 residues of full-length human CFTR
or mutant CFTR (CFTRmut), where the last four residues were re-
placed by glycines were synthesized at University of North Carolina
Peptide Synthesis Facility. Peptides were coupled to an amino-terminal
biotin via the four-residue spacer SGSG and purified by high pressure
liquid chromatography. The skeletal muscle voltage-gated sodium
channel peptide (SkM2; biotin-SPDRDRESIV) (16) was kindly provided
by Dr. Stan Froehner, University of North Carolina.
Biotinylated wild type CFTR, CFTRmut, and SkM2 peptides (25 mg)
were immobilized onto 25 ml of streptavidin-agarose beads (Sigma) in
50 mM Tris, pH 7.5, 1 mM EDTA, and 1 mM EGTA (TEE) overnight at
4 °C. The beads were washed in TEE 1 1% Triton X-100 to remove
unbound peptide. GST-EBP50 fusion protein (25 mg) was immobilized
onto 25 ml of glutathione-agarose beads for 1 h at room temperature in
PBS, and the beads were washed in PBS 1 1% Triton X-100. Five-
hundred mg of CalU3 cell lysate in a total volume of 500 ml was added
to the beads, fresh aliquots of protease inhibitor were added, and the
beads were tumbled at 4 °C for 2 h. Samples were washed in TEE and
bound proteins removed from the beads by boiling in sample buffer. In
some experiments, unbound fractions were precipitated by addition of 1
ml of acetone overnight at 4 °C. Although CFTR was not stable when
precipitated in acetone overnight, we observed CFTR proteolytic frag-
ments with antisera to the R domain or COOH terminus (Not shown).
Bound and unbound fractions were separated on SDS-PAGE gels and
analyzed by immunoblotting with EBP50 or CFTR antisera.
To directly assess binding of CFTR peptides and full-length EBP50,
biotinylated peptides were immobilized as described, and 100 nM GST-
EBP50 was added to the beads in a total volume of 0.5 ml of TEE and
incubated for 2 h at 4 °C. Bound and unbound fractions were analyzed
as described above using mouse anti-GST (Santa Cruz Biotechnology,
Santa Cruz, CA).
Surface Plasmon Resonance—The comparative binding of full-length
EBP50 and EBP50 PDZ domains to CFTR peptides was measured using
surface plasmon resonance (28–30). All experiments were performed on
a BIAcore 2000 instrument at the Macromolecular Interactions Facility
at the University of North Carolina. Biotinylated peptides were immo-
bilized onto neutravidin-coated CM5 sensor chips (BIAcore, Piscat-
away, NJ) as described (16). After injection of 10 mM HCl to remove
unbound peptide, final surface densities varied from 50–100 resonance
units. Purified GST-EBP50 fusion proteins were injected onto the pep-
tide surfaces at a flow rate of 20 ml/min.
RESULTS AND DISCUSSION
Because ezrin is concentrated at the apical membrane of
many epithelia (25, 31), we first determined if EBP50 was
similarly distributed in airway epithelium. Immunohistochem-
ical analysis of sections from human bronchi using antisera
directed against EBP50 demonstrated intense staining of the
apical cell surface with little staining of cilia or internal struc-
tures (Fig. 1). This localization establishes that EBP50 is con-
centrated in airway epithelial cells in the apical compartment,
where CFTR is targeted and functions as a Cl2 channel.
Both ezrin and EBP50 are expressed in several epithelial cell
lines derived from bronchus, colon, and kidney (Fig. 2A), but
not in cells of neuroendocrine origin (not shown). Multiple
EBP50 species are seen in all the cell lines shown, most likely
representing differentially phosphorylated forms (21). Ezrin
and EBP50 are binding partners (21, 32, 33), so these proteins
could form part of a subapical membrane-anchoring complex
specific to epithelia. To evaluate this possibility in airway ep-
ithelial cells, we analyzed the expression and distribution of
CFTR, ezrin, and EBP50 in soluble and particulate fractions
prepared from CalU3 cell lysates. CalU3 cells are a human
airway epithelial cell line that expresses robust levels of CFTR.
CFTR was present only in the particulate fraction, whereas
EBP50 and ezrin were distributed equally in soluble and par-
ticulate fractions (Fig. 2B). Because ezrin and EBP50 do not
have membrane-spanning domains, their presence in the par-
FIG. 1. Confocal microscopy to determine the distribution of
EBP50 in human bronchus. Sections from human bronchi (6–10 mm
thick) were prepared as described. The sections were first incubated
with either an antiserum directed against EBP50 (A) or a pooled normal
rabbit serum (B) and subsequently incubated with Texas Red-conju-
gated goat anti-rabbit IgG. Sections were analyzed using a Leica TCS
4D confocal microscope. Magnification 5 3 430.
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ticulate fraction is consistent with their cytoskeletal origin or
association with membranes through an interaction with inte-
gral membrane proteins of epithelia.
To determine whether CFTR and EBP50 might interact, we
immobilized GST or GST-EBP50 on glutathione-agarose beads
and incubated these affinity resins with CalU3 cell lysates.
Endogenous full-length CFTR was recovered bound to the GST-
EBP50 beads but not to GST beads (Fig. 3A), indicating that
EBP50 and CFTR are capable of interacting. When we per-
formed similar assays in the presence of a peptide correspond-
ing to the COOH-terminal 22 amino acids of CFTR, the asso-
ciation between GST-EBP50 and CFTR was significantly
decreased (Fig. 3B). These results suggest that the COOH
terminus of CFTR is involved in the interaction with EBP50.
Because the CFTR peptide, in which the final four amino acid
residues were replaced by glycines (CFTRmut), failed to block
the association between GST-EBP50 and full-length CFTR
(Fig. 3B), the last four residues of CFTR (DTRL) must play a
critical role in the association.
To determine whether the COOH terminus of CFTR was
sufficient to mediate the interaction with EBP50, we immobi-
lized biotinylated peptides corresponding to the COOH-termi-
nal 22 amino acids of CFTR (Fig. 3B) on streptavidin beads and
incubated the immobilized peptide with CalU3 cell lysates. We
found that EBP50 bound to the CFTR COOH-terminal peptide
and was depleted from the lysate (Fig. 3C). In contrast, there
was no association between EBP50 and the CFTRmut peptide
(Fig. 3C). These data demonstrate that EBP50 and CFTR in-
teract and further demonstrates that the COOH terminus of
CFTR is sufficient to mediate the interaction. To test the spec-
ificity of the interaction between CFTR and EBP50, we per-
formed assays using a peptide derived from the COOH termi-
nus of the skeletal muscle voltage-gated sodium channel
(SkM2) as an affinity ligand. It is known that the SkM2 peptide
can precipitate syntrophins from lysates via a PDZ interaction
(16, 34). SkM2 failed to bind EBP50 (Fig. 3C), demonstrating
that the PDZ domains of EBP50 discriminate between the
cytosolic tails of different proteins containing COOH-terminal
PDZ-binding motifs.
The reciprocal affinity purifications demonstrate that EBP50
and CFTR proteins associate and that the association is medi-
ated by the COOH terminus of CFTR. However, these results
do not distinguish direct binding of CFTR and EBP50 from
binding that occurs via an accessory protein. We used a com-
bination of in vitro binding assays, gel overlays, and surface
plasmon resonance to determine whether CFTR and EBP50
associate directly. EBP50 contains two PDZ domains and has
an ezrin binding site at its extreme COOH terminus (Ref. 33;
Fig. 3A). We immobilized the biotinylated wild type and
CFTRmut peptides on streptavidin-agarose beads and incu-
bated the beads with purified GST-EBP50. Wild type CFTR
bound GST-EBP50, and, as we observed previously, the mutant
CFTR peptide lacking the COOH-terminal DTRL did not (Fig.
4A). We also demonstrated a direct interaction between the
COOH terminus of CFTR and full-length EBP50 in gel overlay
assays (Fig. 4B). Furthermore, we observed that the COOH-
terminal peptide could bind both PDZ1 and PDZ2 of EBP50
(Fig. 4B). Although the CFTR peptide binds PDZ1 and PDZ2 of
EBP50 in overlay (Fig. 4B) and pull-down assays (Not shown),
we did not observe binding of the CFTR peptide to the PDZ
domain of b2-syntrophin (Fig. 4B).
We performed surface plasmon resonance measurements to
compare the relative strength of binding of the CFTR peptide
with the EBP50 PDZ domains. We confirmed that the mutant
CFTR peptide was unable to bind full-length EBP50, even
when tested at very high concentrations (Fig. 4C), and found
that PDZ1 bound the wild type CFTR peptide significantly
better than PDZ2 (Fig. 4D). The apparent binding affinity for
FIG. 2. Distributions of EBP50 and ezrin in epithelial cell lines.
A, whole cell lysates (20 mg) prepared from epithelial cell lines were
analyzed by immunoblotting with rabbit anti-EBP50 (1:10,000) or
mouse anti-ezrin (1:1000) antisera. Proteins were visualized following
incubation with horseradish peroxidase-conjugated secondary antisera
and ECL reagent. B, CalU3 cell homogenates were separated into
soluble and particulate fractions and analyzed by immunoblotting us-
ing rabbit anti-CFTR R domain (1:200), rabbit anti-EBP50 (1:5000), or
mouse anti-ezrin (1:1000). Samples from two separate extractions were
analyzed with similar results.
FIG. 3. Affinity precipitation of EBP50 and CFTR from CalU3
cell lysates. A, GST or GST-EBP50 were immobilized on glutathione-
agarose beads and incubated with ;500 mg of CalU3 cell lysate for 2 h
at 4 °C. The bound fraction was electrophoresed on 7% SDS-PAGE and
immuoblotted with rabbit anti-CFTR R domain (1:200). A schematic of
GST-EBP50 with PDZ1, PDZ2, and the COOH-terminal ezrin binding
domain is shown. B, binding of CFTR to GST-EBP50 was assayed as
described for A in the presence of 400 nM wild type CFTR or CFTRmut
peptide. Binding of CFTR to GST-EBP50 in the presence of CFTR or
CFTRmut peptides was determined by immunoblot analysis as de-
scribed for A. The sequences of wild type CFTR and CFTRmut peptides
are shown. C, CFTR, CFTRmut, and SkM2 peptides were immobilized
on streptavidin-agarose and incubated with ;500 mg of CalU3 cell
lysate for 2 h at 4 °C. The beads were extensively washed, and bound
and unbound fractions were electrophoresed on 10% SDS-PAGE and
immunoblotted with rabbit anti-EBP50 antisera (1:5000).
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PDZ1 was ;40 nM, suggesting a high affinity interaction be-
tween the COOH terminus of CFTR and EBP50. Recently the
rabbit homologue of EBP50 (NHE-RF) was shown to bind the
COOH terminus of the b2-adrenergic receptor via PDZ1(24).
This raises the possibility that the tails of CFTR and the
b2-adrenergic receptor compete for binding to EBP50; however,
it is not well established that the b2-adrenergic receptor is
expressed on apical membranes where CFTR resides.
Our data demonstrate that EBP50 in airway epithelial cells
is concentrated at the apical membrane (Fig. 1), and EBP50
can associate directly with the cytoplasmic tail of the apical
membrane protein, CFTR (Figs. 3 and 4). The association oc-
curs because of the interaction of the terminal DTRL of the
cytoplasmic carboxyl terminus of CFTR with the PDZ domains
in EBP50. The PDZ domains of EBP50 do not recognize the
COOH terminus of SkM2 (Fig. 3A) and the COOH terminus of
CFTR will not interact with the PDZ domain of b2-syntrophin
(Fig. 4B). These observations and the close cellular localization
of CFTR and EBP50 argue that the interactions between
EBP50 and CFTR are specific.
Together with previous data demonstrating that ezrin and
EBP50 interact directly in cells (21), our experiments identify
three members of a potential regulatory complex present at the
apical membrane of airway epithelial cells (Fig. 5). Further-
more, because ezrin is a major actin binding protein in epithe-
lia (25, 35, 36), our results identify EBP50 as an intermediate
for linking an apical membrane protein to the cortical actin
cytoskeleton. Such an interaction provides a mechanism
through which modifications of cytoskeletal structure can be
transmitted to CFTR (37–39). Moreover, the association of
CFTR with a cytoskeletal complex could serve as an anchor
that determines its specific location within microdomains of the
apical membrane (40) or its residence time at the cell surface.
CFTR open probability is regulated by the competing actions of
protein kinases and phosphatases, and ezrin was recently re-
ported to function as an anchoring protein for PKA (41). Thus,
binding to EBP50 may position the phosphorylation sites of
CFTR within close proximity of PKA, and it would not be
surprising if such a complex included other kinases or phos-
phatases that regulate CFTR (42–44).
Because EBP50 contains two PDZ domains (Fig. 3A) and
PDZ1 binds CFTR with higher affinity (Fig. 4D), it is likely that
additional apical proteins interact with PDZ2. Participation of
CFTR and other epithelial ion transport proteins in a common
complex in the subapical compartment could be the basis for
reported functional observations that CFTR influences the ac-
tivity of other epithelial ion transporters (45–49). EBP50 and
E3KARP interact with NHE3 to confer cAMP-induced inhibi-
tion of NHE3 (22, 23). Although NHE3 is not expressed in lung
(50), NHE3 and CFTR are co-expressed in intestinal epithelia.
The interaction of CFTR and NHE3 with subapical scaffolding
proteins may explain why CFTR is also required for cAMP-
mediated inhibition of Na1 absorption driven by Na1/H1 ex-
change in mouse intestine (49). The further characterization of
complexes containing ion transport proteins, scaffolding pro-
teins, and cytoskeletal elements may help explain molecular
mechanisms that regulate epithelial ion transport.
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